Ixo-vec

Ixoberogene soroparvovec · Adverum Biotechnologies, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Ixo-vec, covering 2025-11-18 to 2026-03-19. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) [Phase 3]

See pricing